CD47 and neoplasm: Furthermore, in esophageal squamous carcinoma, anti-CD47 treatment favors the expression of pro-inflammatory cytokines (IL-2 and IL-12, IFN-γ, TNF-β) and increases the tumor-infiltrating CD8+ T cells [264].